In short
This article discusses the use of Foscarnet Sodium Hexahydrate in clinical trials for treating acyclovir-resistant herpes simplex virus (HSV) infections in immunocompromised patients. Foscarnet is being studied as an alternative treatment option when standard antiviral medications like acyclovir are no longer effective. The trials aim to assess the safety and efficacy of Foscarnet in comparison to other treatment options for this challenging patient population.
At a glance
- Drug Name
- Foscarnet Sodium Hexahydrate (Foscavir)
- Formulation
- 24 mg/ml Solution for Infusion
- Administration Route
- Intravenous Use
- Maximum Daily Dose
- 120 mg/kg
- Maximum Total Dose
- 5040 mg/kg
- Treatment Duration
- Up to 42 days
- Target Population
- Immunocompromised patients aged ≥16 years (≥18 in some countries) with acyclovir-resistant mucocutaneous HSV infections
- Primary Endpoint
- Cure rate (all lesions healed) within 28 days of treatment
- Key Secondary Endpoints
- Time to lesion healing, recurrence rates, pain reduction, viral shedding cessation
What is Foscarnet?
Foscarnet Sodium Hexahydrate, also known by its brand name Foscavir, is a medication used to treat certain viral infections. It is particularly important for patients whose immune systems are weakened (immunocompromised) and who have developed resistance to other antiviral medications, such as acyclovir.
Medical Conditions Treated
Foscarnet is primarily used to treat acyclovir-resistant mucocutaneous Herpes Simplex Virus (HSV) infections in immunocompromised patients. Mucocutaneous refers to areas involving both mucous membranes and skin, such as the mouth, genital area, or anal region. This medication is particularly valuable when other treatments have failed.
Immunocompromised patients who might benefit from foscarnet include:
- People with HIV/AIDS
- Organ transplant recipients
- Patients undergoing chemotherapy
- Those on long-term immunosuppressive treatments
How Foscarnet Works
Foscarnet works differently from other antiviral medications like acyclovir. It directly inhibits viral DNA replication by blocking the virus's DNA polymerase enzyme. This mechanism of action makes it effective against viruses that have become resistant to other antiviral drugs.
Administration and Dosage
Foscarnet is administered as an intravenous solution, meaning it's given directly into a vein. The typical concentration is 24 mg/ml. The dosage is usually calculated based on the patient's weight, with a maximum daily dose of 120 mg/kg (milligrams per kilogram of body weight).
Treatment duration can last up to 42 days, depending on the patient's response and the severity of the infection. The total amount of foscarnet given over the entire treatment period should not exceed 5040 mg/kg.
Clinical Trials and Research
Foscarnet is being studied in clinical trials, particularly in comparison to newer antiviral medications. One such trial, named PRIOH-1, is investigating the efficacy and safety of a new drug called pritelivir compared to "Investigator's Choice" treatment (which includes foscarnet) for acyclovir-resistant HSV infections in immunocompromised patients.
In this trial, foscarnet serves as a comparator drug, which means it's being used as a standard treatment to evaluate the effectiveness of the new medication. This highlights the current importance of foscarnet in treating resistant HSV infections.
Potential Side Effects and Precautions
While foscarnet can be an effective treatment, it may cause side effects. Some potential adverse effects mentioned in the clinical trial data include:
- Impairment of renal function
- Seizures
- Genital irritation and/or ulcerations
- Extremity paresthesia (tingling or numbness)
- Nausea
- Changes in blood cell counts (granulocytopenia, anemia, leukopenia, thrombopenia)
- Electrolyte imbalances (hypokalemia, hypocalcemia, hypomagnesemia)
- Diabetes insipidus
- Injection site reactions
- Psychiatric disorders, including anxiety and aggression
Due to these potential side effects, foscarnet is typically used when other treatments have failed or are not suitable. Patients receiving foscarnet should be closely monitored by their healthcare providers.